| Abstract: | Studies conducted for over 20 years allowed the authors to accumulate a rich experience in the production and administration of an inactivated influenza vaccine applicable by nasal and oral route, prepared in the "Stefan S. Nicolau" Institute of Virology. Applied as a monovalent in a single dose of 1000 IU, the vaccine induced seroconversion of 70% of the vaccines and ensured a 2--4-fold decrease in influenza morbidity. Owing to these qualities the vaccine represents one of the most advantageous preparations used in influenza prophylaxis. |
